抗菌药物联合应用治疗肺炎链球菌感染的成本与疗效分析

发布时间：2018-04-08 14:14

本文选题：肺炎链球菌　切入点：感染　出处：《中华医院感染学杂志》2014年14期

【摘要】：目的探讨抗菌药物联合应用治疗肺炎链球菌感染的成本-疗效,寻找最经济治疗肺炎链球菌感染的抗菌药物应用方案。方法选取2013年1-3月肺炎链球菌感染患者108例,随机分为3组,其中A组38例、B组33例、C组37例,A组患者给予头孢哌酮/舒巴坦治疗,B组患者给予氨苄西林/舒巴坦治疗,C组患者给予阿莫西林/克拉维酸治疗,对3组患者的治疗效果和治疗成本进行评价和统计,并计算成本-疗效比。结果 A、B、C 3组治疗有效率分别为86.84%、81.82%和94.59%,3组患者之间临床有效率比较差异有统计学意义(P0.05);A、B、C 3组治疗方案成本-疗效比分别为12.57、13.67和14.16,A组最低,C组方案虽然疗效最好,但是成本疗效比最高,与B方案相比,每增加1单位治疗有效率,C组方案需要增加成本17.30元;进行敏感度分析发现,随着药品价格的下调,3种治疗方案的成本-疗效比分别为11.31、12.30和12.74,与调价前相比改变不大。结论 3种方案对于经济条件较好的患者可以选择阿莫西林/氨苄西林进行治疗,而对于经济状况一般或者较差的患者,则可以选择头孢哌酮/舒巴坦治疗,价格调整对其成本-疗效影响不大。
[Abstract]:Objective to investigate the therapeutic effect of Streptococcus pneumoniae infection: cost - Combined Application of antibiotics for the treatment of antibiotics, the economic application of Streptococcus pneumoniae infection. Methods 108 patients in 2013 1-3 Streptococcus pneumoniae infection, were randomly divided into 3 groups, including 38 cases of A group, B group of 33 cases, 37 cases in C group and A group were treated with Cefoperazone / sulbactam in the treatment, group B was treated with ampicillin / sulbactam in the treatment, C group were treated with amoxicillin / clavulanic acid treatment, evaluation and statistics of 3 groups of patients on treatment effect and cost, and calculate the cost-effectiveness ratio. The results of A, B, C 3 group treatment efficiency were 86.84%, 81.82% and 94.59%, there was statistical significance between the 3 groups of patients with clinical efficiency difference (P0.05); A, B, C of treatment group 3 cost-effectiveness ratio were 12.57,13.67 and 14.16, the lowest in A group, C group although the curative effect is best, but the cost effect The highest ratio compared with B scheme, each 1 unit increase the treatment efficiency, the scheme of C group need to cost 17.30 yuan increase; sensitivity analysis, with reduced the price of drugs, 3 treatment cost-effectiveness ratio were 11.31,12.30 and 12.74, little change compared with the price adjustment before the 3 Schemes for the conclusion. With better economic conditions can choose amoxicillin / ampicillin for treatment, and the general state of the economy or poor patients can choose Cefoperazone / sulbactam in the treatment, the price adjustment has little effect on its cost-effectiveness.

【作者单位】：天津医科大学第二医院药剂科;
【基金】：天津市卫生局基金资助项目(TW-2010B-1023)
【分类号】：R563.1

【参考文献】